113 related articles for article (PubMed ID: 36585187)
1. Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy.
Suckow MA; Hiles MC
Anticancer Res; 2023 Jan; 43(1):335-341. PubMed ID: 36585187
[TBL] [Abstract][Full Text] [Related]
2. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
[TBL] [Abstract][Full Text] [Related]
3. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.
Hodde JP; Suckow MA; Wolter WR; Hiles MC
J Surg Res; 2004 Aug; 120(2):189-94. PubMed ID: 15234212
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
[TBL] [Abstract][Full Text] [Related]
5. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
[TBL] [Abstract][Full Text] [Related]
7. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
[TBL] [Abstract][Full Text] [Related]
9. PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Suckow MA; Wheeler J; Yan M
Can J Vet Res; 2009 Jan; 73(1):39-41. PubMed ID: 19337394
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
11. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of prostate cancer metastasis by administration of a tissue vaccine.
Suckow MA; Wolter WR; Sailes VT
Clin Exp Metastasis; 2008; 25(8):913-8. PubMed ID: 18821060
[TBL] [Abstract][Full Text] [Related]
13. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a tissue vaccine enhances the effect of irradiation on prostate tumors.
Suckow MA; Wheeler J; Wolter WR; Sailes V; Yan M
In Vivo; 2008; 22(2):171-7. PubMed ID: 18468400
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer.
Hrouda D; Todryk SM; Perry MJ; Souberbielle BE; Kayaga J; Kirby RS; Dalgleish AG
BJU Int; 2000 Oct; 86(6):742-8. PubMed ID: 11069388
[TBL] [Abstract][Full Text] [Related]
16. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.
Sinha I; Null K; Wolter W; Suckow MA; King T; Pinto JT; Sinha R
Int J Cancer; 2012 Mar; 130(6):1430-9. PubMed ID: 21500193
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer.
Pollard HB; Levine MA; Eidelman O; Pollard M
In Vivo; 2010; 24(3):249-55. PubMed ID: 20554995
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Hoover DM; Smith GF; Tanzer LR; Merriman RL
J Urol; 1986 Jan; 135(1):163-6. PubMed ID: 3941458
[TBL] [Abstract][Full Text] [Related]
19. Comparison of extracellular matrix enrichment protocols for the improved characterization of the skin matrisome by mass spectrometry.
Dussoyer M; Page A; Delolme F; Rousselle P; Nyström A; Moali C
J Proteomics; 2022 Jan; 251():104397. PubMed ID: 34678517
[TBL] [Abstract][Full Text] [Related]
20. Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy.
Sultanpuram NR; Ahmed U; Peters JT; Zhang T; Wang AZ
Acta Biomater; 2022 Nov; 153():299-307. PubMed ID: 36174938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
